Precision Genomic Testing Market Report 2026

The precision genomic testing market size has grown rapidly in recent years. It will grow from $15 billion in 2025 to $16.75 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to advancements in sequencing technologies, expansion of precision oncology programs, increasing availability of genomic databases, growth in clinical research funding, rising awareness of genetic disorders.

The precision genomic testing market size is expected to see rapid growth in the next few years. It will grow to $25.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, rising investments in genomic research, expansion of population-scale genomic initiatives, growing demand for companion diagnostics, increasing integration of genomics into routine clinical practice. Major trends in the forecast period include increasing adoption of next-generation sequencing, rising use of AI-based genomic interpretation, growing demand for personalized treatment planning, expansion of clinical genomic testing, enhanced integration of bioinformatics platforms.

The rising prevalence of genetic disorders is expected to drive the growth of the precision genomic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual’s DNA, including mutations in a single gene, multiple genes, or alterations in chromosome structure or number. The increasing prevalence of genetic disorders is largely attributed to higher maternal age, as older mothers face an elevated risk of passing chromosomal abnormalities, such as Down syndrome, to their children. Precision genomic testing facilitates early detection and accurate diagnosis of genetic disorders by identifying specific genetic mutations, enabling targeted interventions and personalized treatment strategies. For example, in May 2025, Gene People, a UK-based registered charity, reported that genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK, with approximately 30,000 newborns and children diagnosed with a genetic condition annually. Therefore, the rising prevalence of genetic disorders is fueling the growth of the precision genomic testing market.

Key companies operating in the precision genomic testing market are focusing on developing innovative solutions, such as ultra-sensitive circulating tumor DNA assays, to enable earlier and more accurate cancer detection. Ultra-sensitive circulating tumor DNA assays are advanced tests designed to detect minute fragments of tumor-derived DNA in the blood, supporting early and precise identification of cancer-related genetic mutations. For instance, in April 2025, Natera Inc., a US-based clinical genetic testing company, launched the ultra-sensitive Signatera genome molecular residual disease test. This test leverages whole genome sequencing of both a patient’s tumor and matched normal DNA to create a personalized assay capable of detecting circulating tumor DNA at extremely low levels, down to 1 part per million. This high sensitivity enables earlier and more precise detection of cancer recurrence, improving treatment planning and patient management across multiple cancer types.

In May 2025, QIAGEN N.V., a Netherlands-based life sciences and molecular diagnostics company, acquired Genoox Ltd. for an undisclosed amount. Through this acquisition, QIAGEN N.V. seeks to strengthen its clinical genomics portfolio by integrating Genoox’s AI-driven platform for variant interpretation, enabling faster and more accurate genomic insights for hereditary disease, oncology, and other clinical applications. Genoox Ltd. is an Israel-based genomics technology company specializing in cloud-based AI tools for analyzing, interpreting, and sharing genomic data in clinical and research settings.

Major companies operating in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, BGI Genomics Co. Ltd.

North America was the largest region in the precision genomic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision genomic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the precision genomic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the precision genomic testing market by increasing costs of imported sequencing instruments, reagents, laboratory automation systems, and bioinformatics hardware. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported high-end genomic equipment, while Asia-Pacific faces higher costs for technology imports. These tariffs are increasing testing costs and slowing laboratory expansion plans. However, they are also encouraging domestic production of genomic consumables, regional equipment assembly, and investment in locally developed bioinformatics solutions.

The precision genomic testing market research report is one of a series of new reports that provides precision genomic testing market statistics, including precision genomic testing industry global market size, regional shares, competitors with a precision genomic testing market share, detailed precision genomic testing market segments, market trends and opportunities, and any further data you may need to thrive in the precision genomic testing industry. This precision genomic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision genomic testing refers to the use of advanced genetic analysis to identify specific variations or mutations in a person’s DNA that can influence disease risk, diagnosis, prognosis, or response to treatment. It enables personalized healthcare by tailoring prevention strategies, therapies, and drug choices to an individual’s unique genetic makeup.

The primary products and services of precision genomic testing include consumables, equipment, and services. Consumables are items intended to be used up through regular laboratory processes, such as reagents, printer ink, or other medical supplies. This testing leverages technologies such as next-generation sequencing, polymerase chain reaction (PCR), microarray technology, Sanger sequencing, CRISPR/Cas systems, and others. Applications include oncology, cardiovascular diseases, neurological disorders, reproductive health, rare diseases, and others, serving end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, and others.

The precision genomic testing market consists of revenues earned by entities by providing services such as gene panel testing, whole genome and exome analysis, pharmacogenomics testing, cancer genomics profiling, hereditary disease screening, and bioinformatics-driven interpretation of genetic data. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision genomic testing market also includes sales of hybridization buffers and enzymes, targeted gene panels, library preparation kits, genomic data compression tools, and rare mutation detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.